SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, Autologous, TCR

March 07, 2023

Strategic Merger of Adaptimmune and TCR2 Tx; Afami-cel's BLA Filing Completion on Track for Mid-2023; Progress in ADP-A2M4CD8’s Clinical Development; Adaptimmune Q4 2022 Earnings Call Summary

Here is a brief preview of this blast: On Monday, March 6, Adaptimmune held its Q4 and FY 2022 earnings call (press release / presentation) highlighting an agreement with TCR2 Tx for merging into a preeminent cell therapy company focused on treating solid tumors (press release). Additionally, management presented updates from afami-cel’s (autologous MAGE-A4 SPEAR-T) BLA filing in synovial sarcoma and ADP-A2M4CD8’s (autologous MAGE-A4 TCR-T) Ph2 SURPASS-3 trial in ovarian cancer. Below, Celltelligence provides insights on the decision of Adaptimmune to partner with TCR2 Tx while discussing the potential of their combined pipeline in the treatment of solid tumors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.